Notification That Annual Report Will Be Submitted Late (nt 10-k)
April 02 2018 - 6:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
SEC
FILE NUMBER: 000-54856
(Check
One): [
X
] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form
10-D [ ] Form N-SAR
[ ] Form N-CSR
For
Period Ended: December 31, 2017
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-QSB
[ ] Transition Report on Form N-SAR
For
the Transition Period Ended:
Nothing
in this form shall be construed to imply that the Commission has verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I - REGISTRATION INFORMATION
OWC
Pharmaceutical Research Corp.
Full
Name of Registrant
Former
Name if Applicable
2
Ben Gurion St
Address
of Principal Executive Office
(Street and Number)
Ramat
Gan, 5257334, Israel
City,
State and Zip Code
PART
II - RULE 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
|
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
[
X]
|
|
(b)
|
The
subject annual report on Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date;
or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth
calendar day following the prescribed due date.
|
|
|
(c)
|
The
accountants statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III – NARRATIVE
The
Company is unable, without reasonable effort and expense, to file its Annual Report on Form 10-K for the year ended December 31,
2017 within the prescribed time period because of the additional time that the Company requires to finalize its Form 10-K for
the fiscal year ended December 31, 2017, as a result of a change in legal representation. The Company expects to file the 2017
Form 10-K within the extension period of fifteen calendar days provided under Rule 12b-25 under the Securities Exchange Act of
1934, as amended.
PART
IV - OTHER INFORMATION
(1)
Name and telephone number of person to contact in regard to this notification.
Mordechi
Bignitz, CEO
(Name)
+972-3-917-1921
(Area
Code) (Telephone Number)
(2)
Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file
such report(s) been filed? If answer is no, identify report(s).
[
X
]
Yes [ ] No
(3)
Is it anticipated that any significant changes in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof?
[ ]
Yes [
X
] No
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
OWC
Pharmaceutical Research Corp.
Name
of Registrant as Specified in Charter
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
|
April 2, 2018
|
|
|
|
By:
|
/s/
Mordechi Bignitz
|
|
|
Mordechi
Bignitz, CEO
|
|
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Sep 2023 to Sep 2024